Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial - 征途国际

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04559-4In a phase 1 trial evaluating GFH375, an oral, dual on–off binding KRAS G12D inhibitor, in patients with KRASG12D-mutated solid tumors, there was one treatment-related death, while most treatment-related adverse even...